# Prognostic relevance of PRSS2 and its immune correlates in papillary thyroid carcinoma

## TL;DR

This study finds that high PRSS2 levels in papillary thyroid cancer are linked to better survival and immune-related genes, suggesting a role in the tumor's immune environment.

## Contribution

The study identifies PRSS2 as a prognostic marker in papillary thyroid carcinoma and links it to immune-related genes.

## Key findings

- PRSS2 is upregulated in papillary thyroid carcinoma tissues.
- High PRSS2 expression correlates with better survival, especially in older patients and those with advanced stages.
- PRSS2 shows strong positive correlations with immune-related genes like TRBV, CD40, and TGF-beta-stimulated genes.

## Abstract

Papillary thyroid carcinoma (PTC) generally exhibits favorable prognosis; however, a subset of patients remains at risk for recurrence. Serine protease 2 (PRSS2) was an oncogenic factor in several solid tumors, yet its expression profile and functional role in PTC remain poorly defined. This study aimed to investigate the expression level of PRSS2 in PTC and its prognostic significance, as well as explore its potential involvement in immune regulatory mechanisms.

PTC specimens from thyroidectomy patients were analyzed by transcriptomic analysis, quantitative real-time PCR, and immunohistochemistry. Differential gene expression and survival analyses were performed by integrating data from TCGA and GEO databases. Pearson correlation analysis was utilized to evaluate associations between PRSS2 and immune-related genes.

PRSS2 was upregulated in PTC tissues. High PRSS2 expression was associated with better survival (HR = 3.253; 95% CI: 1.155–9.160), especially in patients aged ≥62 and stage II/III. Patients with low PRSS2 and high BRAF expression exhibited a markedly reduced 5-year overall survival rate. PRSS2 also showed significant positive correlations with multiple immune-related genes, including a moderate to strong correlation with T-cell receptor beta variable (TRBV) region genes (R = 0.58–0.72), CD40, and transforming growth factor beta-stimulated clone 22 domain 1.

PRSS2 is upregulated in PTC and is associated with favorable prognosis. Its association with TRBV and other immune-related genes suggests a correlation with tumor immune microenvironment. Further studies are needed to elucidate the biological functions of PRSS2 in PTC and to assess therapeutic potential.